Time-dependency in population PK of etrolizumab in patients with moderately-to-severely active UC – a reflection of disease improvement?
When the population PK of etrolizumab in patients with moderately-to-severely active UC was described (two-compartment model with first-order absorption and elimination), a decrease in clearance was